Developer docs
API playgroundTry for free, no card

Search company profiles

Extend Biosciences

Full company profile

uuid0004cfg

Namestring
Extend Biosciences
Legal namestring
Extend Biosciences Inc.
Websiteurl
extendbio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Extend Biosciences Inc. is a privately-held, clinical-stage biotechnology company headquartered at 90 Bridge Street, Newton, Massachusetts, founded in 2012-2013 around the proprietary D-VITylation® drug delivery platform technology. The platform covalently attaches a vitamin D derivative site-specifically to peptide or protein therapeutics; the conjugate is recognized by Vitamin D Binding Protein (VDBP), which actively transports it into circulation and extends its half-life, with preclinical data showing peptide half-life extension from minutes to hours and translation potential to once-weekly subcutaneous dosing in humans, while improving bioavailability without the bulk-driven loss of functional activity associated with PEG or protein fusion approaches.

The company's pipeline is anchored by EXT608, a long-acting D-VITylated PTH(1-34) for hypoparathyroidism (a rare disease typically caused by inadvertent parathyroid gland removal during neck surgery, with no current hormone-replacement option), which has FDA Orphan Drug Designation and is currently in Phase 2 clinical trials supported by FDA OOPD, NIDDK, and MassVentures funding. A second asset, EXT418, applies the platform to ghrelin for diabetes-induced peripheral neuropathy (a non-opioid, potentially disease-modifying therapy) and cancer cachexia (a metabolic syndrome with no FDA-approved therapy), with IND-ready efficacy data. Additional earlier-stage D-VITylated programs target alcoholic liver disease, acute radiation syndrome, and military opioid countermeasures. Three issued US patents and a registered D-VITylation® trademark protect the underlying IP.

The business model is dual-track: revenue is intended to flow from strategic alliances and licensing of the D-VITylation® platform to pharmaceutical partners for both partner proprietary assets and Extend's own pipeline, supplemented by potential one-time licensing economics on proprietary therapeutic candidates. To date the company has not disclosed any licensing deal. The customer base is therefore twofold: rare disease patient populations (hypoparathyroidism, peripheral neuropathy, cancer cachexia) as end beneficiaries, and pharmaceutical companies as upstream platform licensees. The company has been funded almost entirely through non-dilutive SBIR/STTR grants from NIH (NIDDK, NCI, NINDS, NIAID, NIAAA), NSF, DoD, FDA OOPD, and Massachusetts state agencies (MassVentures, MLSC), with no disclosed venture capital backing and a 1-10 employee footprint.

Short descriptiontext

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® peptide drug delivery platform, with lead asset EXT608 in Phase 2 for hypoparathyroidism and IND-ready EXT418 targeting peripheral neuropathy and cancer cachexia. The company pursues licensing and strategic alliance revenue from pharmaceutical partners while serving rare disease patient populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery platform, peptide therapeutics, half-life extension, biologics development, biopharmaceutical research
Industry3 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Drug Delivery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Alliances and Licensing
TypeLicensing Royalties
Description

The company enters into strategic alliances with partners for discovery, development and commercialization of therapeutic peptides and proteins. Revenue may come from licensing the D-VITylation technology platform and co-developing partner proprietary entities.

extendbio.com
2Therapeutic Development and Commercialization
TypeOne Time License
Description

Development and potential commercialization of proprietary therapeutic candidates in the pipeline including EXT608 for hypoparathyroidism, EXT418 for cachexia and peripheral neuropathy.

extendbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® platform technology that improves the pharmacokinetic properties of peptides and proteins by covalently attaching a vitamin D derivative, enabling recognition by Vitamin D Binding Protein (VDBP) for active transport and extended circulation. Its internal pipeline includes EXT608 (long-acting PTH for hypoparathyroidism, currently in Phase 2 clinical trials) and EXT418 (long-acting ghrelin for cancer cachexia and peripheral neuropathy, IND-ready), while the platform is also offered for licensing and co-development with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Half-life extension from minutes to hours in rats
+2 more records
Product overview1 text field

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® drug delivery platform technology that improves pharmacokinetic properties of peptides and proteins. The platform works by covalently attaching a vitamin D derivative to therapeutic peptides, which are then recognized by Vitamin D Binding Protein (VDBP) for active transport into circulation. The pipeline includes EXT608 (long-acting PTH for hypoparathyroidism, Phase 2) and EXT418 (long-acting ghrelin for peripheral neuropathy and cancer cachexia, IND-ready), along with other D-VITylated peptides under development for chronic diseases.

Product and service3 records
1D-VITylation® Platform Technology
CategoryCore platform technology / drug delivery
Description

Proprietary drug delivery platform technology that harnesses the biology of vitamin D to prolong the half-life and enhance the absorption and bioavailability of peptides and proteins when delivered subcutaneously. A vitamin D derivative is covalently attached site-specifically to the therapeutic, recognized by Vitamin D Binding Protein (VDBP), which transports the conjugate into circulation for extended duration. Used internally to develop pipeline assets and offered for licensing and co-development with pharmaceutical partners.

2EXT608
CategoryPipeline compound / therapeutic peptide
Description

Long-acting D-VITylated PTH(1-34) conjugate for the treatment of hypoparathyroidism. A subcutaneously administered PTH derivative with pharmacokinetic profile that mimics physiological PTH levels, returning and maintaining serum calcium and phosphate within normal range. Currently in Phase 2 clinical trials; received FDA Orphan Drug Designation in May 2022 providing seven years of market exclusivity upon approval.

3EXT418
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierNotableTypeGTM or Marketing PartnerAnnounced on2024-02-21
Description

Extend Biosciences became a founding member of the AmCham Abu Dhabi Biotech Committee. Founder Tarik Soliman, PhD traveled to Abu Dhabi and Dubai, United Arab Emirates to attend the Partnership Summit: Elevating Business Collaboration in Abu Dhabi.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with the laboratory of Jose Garcia, MD, PhD at the University of Washington resulted in a peer-reviewed publication titled 'EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice' published in Journal of Cachexia, Sarcopenia and Muscle.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with fellow LabCentral resident company Advirna as well as Duke University for a Phase I SBIR grant from NIAAA to work on a program for alcoholic liver disease (ALD).

4Women In Bio
Strategic tierMinorTypeGTM or Marketing Partner
Description

Founder Laura Hales participated in WIB Lobster Pot pitch competition, a Shark Tank-style event sponsored by Women In Bio held at LabCentral, winning first prize.

extendbio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Zealand Pharma develops long-acting peptide therapeutics using stabilized peptide chemistries, with approved dasiglucagon (Zegalogue). The company's peptide half-life extension focus and rare-disease/endocrinology pipeline overlap meaningfully with Extend Biosciences' D-VITylation approach.

TypeBroad incumbent
Description

Takeda markets Natpara (parathyroid hormone for hypoparathyroidism), the only FDA-approved PTH therapy for the indication EXT608 targets. As the incumbent in the same disease, Takeda defines the competitive and pricing reference point for Extend Biosciences' lead asset.

TypeDirect peer
Description

Halozyme's ENHANZE platform uses recombinant human hyaluronidase (rHuPH20) to enable rapid subcutaneous delivery of large-volume biologics. Like Extend Biosciences, Halozyme licenses its delivery technology to pharma partners to improve administration and PK properties of injectable therapeutics.

4Amunix Pharmaceuticals
TypeEmerging player
Description

Amunix (acquired by Sanofi) developed XTEN and other half-life extension technologies for peptides and proteins. Its mask/conjugation-based approach to prolonging PK is methodologically adjacent to D-VITylation and serves as a useful comparand for platform economics and partner interest.

TypeEmerging player
Description

MannKind develops alternative delivery technologies for peptides and proteins, most notably inhaled insulin (Afrezza) and dry-powder formulations. Its focus on non-injectable peptide delivery overlaps thematically with Extend Biosciences' mission of improving peptide pharmacokinetics and patient experience.

TypeBroad incumbent
Description

Novo Nordisk is a global leader in peptide/protein therapeutics, particularly in endocrine disorders, with extensive work on long-acting insulins, GLP-1, and PTH analogues. Its scale, manufacturing infrastructure, and licensing/sourcing patterns shape the partner landscape for peptide half-life extension companies like Extend Biosciences.

TypeEmerging player
Description

Protagonist develops disulfide-stabilized peptides (PNPs) for endocrine and hematology indications, including clinical-stage assets in rare diseases. It is comparable to Extend Biosciences in its platform approach to engineering peptides with improved pharmacological properties.

TypeBroad incumbent
Description

Lilly is a major developer of peptide/protein therapeutics (e.g., insulin, dulaglutide, teriparatide/Forteo) and historically active in PTH and osteoporosis. As a large incumbent with established peptide franchises, Lilly is a relevant comparator and potential strategic partner for Extend Biosciences' D-VITylation platform.

TypeDirect peer
Description

Crinetics is a clinical-stage peptide therapeutics company focused on rare endocrine diseases, with lead asset paltusotine (somatostatin agonist). Comparable to Extend Biosciences in developing long-acting peptide therapeutics for underserved endocrine indications and pursuing platform expansion.

TypeDirect peer
Description

Ascendis Pharma develops TransCon technology, a transient linker-based prodrug platform that prolongs half-life of peptides, proteins, and small molecules. It is the closest comparable to Extend Biosciences' D-VITylation, both tackling half-life extension and subcutaneous bioavailability for therapeutic peptides including PTH (TransCon PTH for hypoparathyroidism).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Extend Biosciences

Biopharmaceutical Drug Delivery Platformextendbio.com

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® peptide drug delivery platform, with lead asset EXT608 in Phase 2 for hypoparathyroidism and IND-ready EXT418 targeting peripheral neuropathy and cancer cachexia. The company pursues licensing and strategic alliance revenue from pharmaceutical partners while serving rare disease patient populations.

What Extend Biosciences does

Extend Biosciences Inc. is a privately-held, clinical-stage biotechnology company headquartered at 90 Bridge Street, Newton, Massachusetts, founded in 2012-2013 around the proprietary D-VITylation® drug delivery platform technology. The platform covalently attaches a vitamin D derivative site-specifically to peptide or protein therapeutics; the conjugate is recognized by Vitamin D Binding Protein (VDBP), which actively transports it into circulation and extends its half-life, with preclinical data showing peptide half-life extension from minutes to hours and translation potential to once-weekly subcutaneous dosing in humans, while improving bioavailability without the bulk-driven loss of functional activity associated with PEG or protein fusion approaches.

The company's pipeline is anchored by EXT608, a long-acting D-VITylated PTH(1-34) for hypoparathyroidism (a rare disease typically caused by inadvertent parathyroid gland removal during neck surgery, with no current hormone-replacement option), which has FDA Orphan Drug Designation and is currently in Phase 2 clinical trials supported by FDA OOPD, NIDDK, and MassVentures funding. A second asset, EXT418, applies the platform to ghrelin for diabetes-induced peripheral neuropathy (a non-opioid, potentially disease-modifying therapy) and cancer cachexia (a metabolic syndrome with no FDA-approved therapy), with IND-ready efficacy data. Additional earlier-stage D-VITylated programs target alcoholic liver disease, acute radiation syndrome, and military opioid countermeasures. Three issued US patents and a registered D-VITylation® trademark protect the underlying IP.

The business model is dual-track: revenue is intended to flow from strategic alliances and licensing of the D-VITylation® platform to pharmaceutical partners for both partner proprietary assets and Extend's own pipeline, supplemented by potential one-time licensing economics on proprietary therapeutic candidates. To date the company has not disclosed any licensing deal. The customer base is therefore twofold: rare disease patient populations (hypoparathyroidism, peripheral neuropathy, cancer cachexia) as end beneficiaries, and pharmaceutical companies as upstream platform licensees. The company has been funded almost entirely through non-dilutive SBIR/STTR grants from NIH (NIDDK, NCI, NINDS, NIAID, NIAAA), NSF, DoD, FDA OOPD, and Massachusetts state agencies (MassVentures, MLSC), with no disclosed venture capital backing and a 1-10 employee footprint.

Extend Biosciences firmographics

Firmographics
Name
Extend Biosciences
Legal name
Extend Biosciences Inc.
Website
https://extendbio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® peptide drug delivery platform, with lead asset EXT608 in Phase 2 for hypoparathyroidism and IND-ready EXT418 targeting peripheral neuropathy and cancer cachexia. The company pursues licensing and strategic alliance revenue from pharmaceutical partners while serving rare disease patient populations.
Ownership category
akta.pro rank

Extend Biosciences industry classification

Industry
Product category
Biopharmaceutical Drug Delivery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug delivery platform
  • Peptide therapeutics
  • Half-life extension
  • Biologics development
  • Biopharmaceutical research

Where Extend Biosciences is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Extend Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Alliances and Licensing: The company enters into strategic alliances with partners for discovery, development and commercialization of therapeutic peptides and proteins. Revenue may come from licensing the D-VITylation technology platform and co-developing partner proprietary entities.
  2. Therapeutic Development and Commercialization: Development and potential commercialization of proprietary therapeutic candidates in the pipeline including EXT608 for hypoparathyroidism, EXT418 for cachexia and peripheral neuropathy.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Extend Biosciences product offering

Product offering

Core offering

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® platform technology that improves the pharmacokinetic properties of peptides and proteins by covalently attaching a vitamin D derivative, enabling recognition by Vitamin D Binding Protein (VDBP) for active transport and extended circulation. Its internal pipeline includes EXT608 (long-acting PTH for hypoparathyroidism, currently in Phase 2 clinical trials) and EXT418 (long-acting ghrelin for cancer cachexia and peripheral neuropathy, IND-ready), while the platform is also offered for licensing and co-development with pharmaceutical partners.

Product overview

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® drug delivery platform technology that improves pharmacokinetic properties of peptides and proteins. The platform works by covalently attaching a vitamin D derivative to therapeutic peptides, which are then recognized by Vitamin D Binding Protein (VDBP) for active transport into circulation. The pipeline includes EXT608 (long-acting PTH for hypoparathyroidism, Phase 2) and EXT418 (long-acting ghrelin for peripheral neuropathy and cancer cachexia, IND-ready), along with other D-VITylated peptides under development for chronic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • D-VITylation® Platform Technology Proprietary drug delivery platform technology that harnesses the biology of vitamin D to prolong the half-life and enhance the absorption and bioavailability of peptides and proteins when delivered subcutaneously. A vitamin D derivative is covalently attached site-specifically to the therapeutic, recognized by Vitamin D Binding Protein (VDBP), which transports the conjugate into circulation for extended duration. Used internally to develop pipeline assets and offered for licensing and co-development with pharmaceutical partners.
  • EXT608 Long-acting D-VITylated PTH(1-34) conjugate for the treatment of hypoparathyroidism. A subcutaneously administered PTH derivative with pharmacokinetic profile that mimics physiological PTH levels, returning and maintaining serum calcium and phosphate within normal range. Currently in Phase 2 clinical trials; received FDA Orphan Drug Designation in May 2022 providing seven years of market exclusivity upon approval.
  • EXT418

Quantifiable outcome

  • Half-life extension from minutes to hours in rats
  • +2 more outcomes

Companies that use Extend Biosciences

Customer profile

Segments3 records

Ideal customer profiles3 records

Extend Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Extend Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered notable, core and minor.

  • AmCham Abu Dhabi Biotech CommitteenotableGTM or Marketing Partner · 21 February 2024Extend Biosciences became a founding member of the AmCham Abu Dhabi Biotech Committee. Founder Tarik Soliman, PhD traveled to Abu Dhabi and Dubai, United Arab Emirates to attend the Partnership Summit: Elevating Business Collaboration in Abu Dhabi.
  • University of Washington (Jose Garcia, MD, PhD Laboratory)coreStrategic or Co-development PartnerCollaboration with the laboratory of Jose Garcia, MD, PhD at the University of Washington resulted in a peer-reviewed publication titled 'EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice' published in Journal of Cachexia, Sarcopenia and Muscle.
  • AdvirnaminorStrategic or Co-development PartnerCollaboration with fellow LabCentral resident company Advirna as well as Duke University for a Phase I SBIR grant from NIAAA to work on a program for alcoholic liver disease (ALD).
  • Women In BiominorGTM or Marketing PartnerFounder Laura Hales participated in WIB Lobster Pot pitch competition, a Shark Tank-style event sponsored by Women In Bio held at LabCentral, winning first prize.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Extend Biosciences competitors and assessment

Company assessment

Direct peers

  • Zealand Pharma: Zealand Pharma develops long-acting peptide therapeutics using stabilized peptide chemistries, with approved dasiglucagon (Zegalogue). The company's peptide half-life extension focus and rare-disease/endocrinology pipeline overlap meaningfully with Extend Biosciences' D-VITylation approach.
  • Halozyme Therapeutics: Halozyme's ENHANZE platform uses recombinant human hyaluronidase (rHuPH20) to enable rapid subcutaneous delivery of large-volume biologics. Like Extend Biosciences, Halozyme licenses its delivery technology to pharma partners to improve administration and PK properties of injectable therapeutics.
  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage peptide therapeutics company focused on rare endocrine diseases, with lead asset paltusotine (somatostatin agonist). Comparable to Extend Biosciences in developing long-acting peptide therapeutics for underserved endocrine indications and pursuing platform expansion.
  • Ascendis Pharma: Ascendis Pharma develops TransCon technology, a transient linker-based prodrug platform that prolongs half-life of peptides, proteins, and small molecules. It is the closest comparable to Extend Biosciences' D-VITylation, both tackling half-life extension and subcutaneous bioavailability for therapeutic peptides including PTH (TransCon PTH for hypoparathyroidism).

Broad incumbents

  • Takeda Pharmaceutical (Shire / Natpara): Takeda markets Natpara (parathyroid hormone for hypoparathyroidism), the only FDA-approved PTH therapy for the indication EXT608 targets. As the incumbent in the same disease, Takeda defines the competitive and pricing reference point for Extend Biosciences' lead asset.
  • Novo Nordisk: Novo Nordisk is a global leader in peptide/protein therapeutics, particularly in endocrine disorders, with extensive work on long-acting insulins, GLP-1, and PTH analogues. Its scale, manufacturing infrastructure, and licensing/sourcing patterns shape the partner landscape for peptide half-life extension companies like Extend Biosciences.
  • Eli Lilly: Lilly is a major developer of peptide/protein therapeutics (e.g., insulin, dulaglutide, teriparatide/Forteo) and historically active in PTH and osteoporosis. As a large incumbent with established peptide franchises, Lilly is a relevant comparator and potential strategic partner for Extend Biosciences' D-VITylation platform.

Emerging players

  • Amunix Pharmaceuticals: Amunix (acquired by Sanofi) developed XTEN and other half-life extension technologies for peptides and proteins. Its mask/conjugation-based approach to prolonging PK is methodologically adjacent to D-VITylation and serves as a useful comparand for platform economics and partner interest.
  • MannKind Corporation: MannKind develops alternative delivery technologies for peptides and proteins, most notably inhaled insulin (Afrezza) and dry-powder formulations. Its focus on non-injectable peptide delivery overlaps thematically with Extend Biosciences' mission of improving peptide pharmacokinetics and patient experience.
  • Protagonist Therapeutics: Protagonist develops disulfide-stabilized peptides (PNPs) for endocrine and hematology indications, including clinical-stage assets in rare diseases. It is comparable to Extend Biosciences in its platform approach to engineering peptides with improved pharmacological properties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Extend Biosciences social profiles

Digital presence

Extend Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Extend Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Extend Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Extend Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extend Biosciences

What does Extend Biosciences do?

Extend Biosciences is a clinical-stage biotechnology company developing the proprietary D-VITylation® platform technology that improves the pharmacokinetic properties of peptides and proteins by covalently attaching a vitamin D derivative, enabling recognition by Vitamin D Binding Protein (VDBP) for active transport and extended circulation. Its internal pipeline includes EXT608 (long-acting PTH for hypoparathyroidism, currently in Phase 2 clinical trials) and EXT418 (long-acting ghrelin for cancer cachexia and peripheral neuropathy, IND-ready), while the platform is also offered for licensing and co-development with pharmaceutical partners.

Is Extend Biosciences a public or private company?

Extend Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Extend Biosciences founded?

Extend Biosciences was founded in 2013. It employs 1 to 10 people.

Where is Extend Biosciences based?

Extend Biosciences is headquartered in Newton, United States, in the North America region.

How does Extend Biosciences make money?

Two revenue lines are on record. Strategic Alliances and Licensing is the primary driver. The others are therapeutic Development and Commercialization.

Who are Extend Biosciences's main competitors?

Direct peers on record are Zealand Pharma, Halozyme Therapeutics, Crinetics Pharmaceuticals and Ascendis Pharma. Broad incumbents are Takeda Pharmaceutical (Shire / Natpara), Novo Nordisk and Eli Lilly. Emerging players are Amunix Pharmaceuticals, MannKind Corporation and Protagonist Therapeutics.

Does Extend Biosciences have an API?

No public API is recorded for Extend Biosciences.

What industry is Extend Biosciences in?

Extend Biosciences's product category is Biopharmaceutical Drug Delivery Platform. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals